Analysts’ Recent Ratings Changes for OPKO Health (OPK)

OPKO Health (NASDAQ: OPK) has recently received a number of price target changes and ratings updates:

• 3/19/2025 – OPKO Health had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
• 3/12/2025 – OPKO Health had its “outperform” rating reaffirmed by analysts at Barrington Research. They now have a $2.25 price target on the stock.
• 3/12/2025 – OPKO Health had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
• 3/3/2025 – OPKO Health was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 3/3/2025 – OPKO Health had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
• 2/28/2025 – OPKO Health had its “outperform” rating reaffirmed by analysts at Barrington Research. They now have a $2.25 price target on the stock.

OPKO Health Stock Performance

Shares of OPKO Health stock opened at $1.86 on Thursday. OPKO Health, Inc. has a fifty-two week low of $0.87 and a fifty-two week high of $2.04. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The firm has a market capitalization of $1.25 billion, a P/E ratio of -9.79 and a beta of 1.70. The company’s 50 day moving average price is $1.64 and its two-hundred day moving average price is $1.57.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.09. The firm had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. On average, equities analysts forecast that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Phillip Md Et Al Frost bought 200,000 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was acquired at an average price of $1.74 per share, with a total value of $348,000.00. Following the completion of the purchase, the chief executive officer now directly owns 213,501,448 shares of the company’s stock, valued at approximately $371,492,519.52. This represents a 0.09 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Over the last 90 days, insiders acquired 964,971 shares of company stock valued at $1,493,692. Insiders own 47.26% of the company’s stock.

Institutional Investors Weigh In On OPKO Health

A number of large investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of OPKO Health by 4.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 186,783 shares of the biotechnology company’s stock valued at $275,000 after buying an additional 8,064 shares during the last quarter. Two Sigma Advisers LP boosted its holdings in OPKO Health by 2.3% during the fourth quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company’s stock worth $560,000 after purchasing an additional 8,396 shares during the last quarter. FMR LLC boosted its holdings in OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in OPKO Health by 75.3% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 12,417 shares during the last quarter. Finally, Comerica Bank boosted its holdings in OPKO Health by 18.2% during the fourth quarter. Comerica Bank now owns 106,369 shares of the biotechnology company’s stock worth $156,000 after purchasing an additional 16,369 shares during the last quarter. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.